Cabergoline

An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.

Also Known As:

1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; Cabaser; Cabaseril; Cabergoline Diphosphate; Dostinex; FCE 21336; FCE-21336; Galastop; Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-

Networked: 1117 relevant articles (201 outcomes, 213 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Ergot Alkaloids: 208
    - Ergolines: 109
      - Cabergoline: 1117
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Ergolines: 109
      - Cabergoline: 1117

Experts

1.	Colao, Annamaria: 36 articles (01/2021 - 06/2002)
2.	Pivonello, Rosario: 25 articles (01/2021 - 06/2002)
3.	Lombardi, Gaetano: 18 articles (01/2009 - 06/2002)
4.	Wu, Zhe Bao: 11 articles (01/2021 - 11/2015)
5.	Molitch, Mark E: 11 articles (02/2017 - 10/2002)
6.	Auriemma, Renata S: 10 articles (01/2021 - 01/2013)
7.	Colao, A: 10 articles (03/2015 - 01/2000)
8.	Shimon, Ilan: 9 articles (10/2022 - 02/2007)
9.	Casulari, Luiz Augusto: 9 articles (06/2019 - 01/2004)
10.	Hofland, Leo J: 8 articles (01/2019 - 05/2004)

Related Diseases

1.	Prolactinoma (Prolactinomas) 01/01/2020 - "CLHs significantly improved after cabergoline administration in 7/9 patients with a lactotroph adenoma (77.7 % response rate). " 01/01/2015 - "Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey." 04/01/2010 - "Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas." 01/01/2019 - "However, Cabergoline treatment was more effective in idiopathic hyperprolactinemic than prolactinoma patients." 04/01/1997 - "Although the present data were not obtained in a formal study we conclude that cabergoline is an effective and well-tolerated treatment for macroprolactinoma patients."
2.	Neoplasms (Cancer) 10/01/2020 - "SST2 analogs have demonstrated only very limited antitumor effect, while high-dose cabergoline has been more effective in preventing tumor regrowth, but still in only a minority of cases. " 09/15/2016 - "It is not clear whether cabergoline is also more effective with respect to tumor growth because the certainty of the evidence is very low. " 01/01/2008 - "Cabergoline normalized serum PRL level, shrank the tumor mass remarkably, and caused marked improvement of visual acuity. " 11/01/2012 - "Rapid improvement in visual field with cabergoline in suprasellar tumor in a young adult: Clinical dilemma solved and surgery averted." 06/01/1996 - "During two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during cabergoline administration, and three patients have experienced a further decline in PRL and/or tumor size. "
3.	Hyperprolactinemia 03/01/1997 - "Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia. " 02/01/2017 - "Recurrences of hyperprolactinaemia were observed in 3 of 11 (27%) postwithdrawal patients at a median time of 3·0 (range; 2·9-11·2) months, indicating that a high percentage (73%) maintained remission for at least 12 months after cabergoline cessation. " 11/01/2021 - "Cabergoline has been demonstrated to be effective and should be considered as a first-line treatment for hyperprolactinemia. " 06/01/1989 - "We conclude that cabergoline is effective treatment for hyperprolactinemia. " 11/01/2021 - "This study aimed to evaluate cabergoline's effectiveness, along with transsphenoidal surgery, in the treatment of hyperprolactinemia. "
4.	Acromegaly 01/01/2020 - "A trial of cabergoline monotherapy can be effective in patients with biochemically mild acromegaly. " 05/01/2011 - "Cabergoline is widely considered to be poorly effective in acromegaly. " 01/01/2004 - "Fourteen other patients with more typical, active postoperative acromegaly were administered cabergoline in a 6-month, open label, dose-escalation study. " 02/01/1998 - "Cabergoline in the treatment of acromegaly: a study in 64 patients." 06/01/1997 - "Cabergoline treatment of acromegaly: a preliminary dose finding study."
5.	Parkinson Disease (Parkinson's Disease) 11/01/1996 - "Our results indicate that the long-lasting effects of cabergoline could be beneficial for treating Parkinson's disease." 09/13/2002 - "While cabergoline is commonly used to treat the motor dysfunction of Parkinson's disease, it may also be effective in inhibiting oxidative stress, a possible mechanism of dopaminergic neuronal degeneration in Parkinson's disease." 01/01/2001 - "Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease." 12/01/1994 - "Cabergoline improved motor control in patients with Parkinson's disease who were experiencing clinical fluctuations. " 03/01/2014 - "In this study, we aimed to evaluate the impact of cabergoline use in patients with Parkinson's disease on valvular and biventricular functions. "

Related Drugs and Biologics

1.	Prolactin
2.	Dopamine Agonists (Dopamine Agonist)
3.	Bromocriptine (Parlodel)
4.	Levodopa (L Dopa)
5.	Somatostatin (Somatotropin Release-Inhibiting Factor)
6.	Octreotide (Sandostatin)
7.	Insulin-Like Growth Factor I (IGF-1)
8.	pasireotide
9.	Gonadotropin-Releasing Hormone (GnRH)
10.	Pergolide (Permax)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Oral Administration
4.	Aftercare (After-Treatment)
5.	Operative Surgical Procedures